Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 5/20 | 0.46 |
| ▸ | DRD3 | P35462 | 5/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18134266 | 0.73 | MAPT (0.75) | PLAUMAPTNFKB1THPOHIF1A | |
| SCHEMBL20992186 | 0.73 | ALDH1A1 (0.36) | ALDH1A1KDM4E | |
| SCHEMBL4425472 | 0.72 | NCF1 (0.34) | — | |
| SCHEMBL30368725 | 0.70 | PLAU (1.00) | PLAUMAPTNFKB1THPOHIF1A | |
| SCHEMBL29428767 | 0.70 | PLAU (1.00) | PLAUMAPTNFKB1THPOHIF1A | |
| SCHEMBL895905 | 0.70 | PLAU (1.00) | PLAUMAPTNFKB1THPOHIF1A | |
| SCHEMBL896147 | 0.70 | PLAU (1.00) | PLAUMAPTNFKB1THPOHIF1A | |
| SCHEMBL42952 | 0.70 | PLAU (1.00) | PLAUMAPTNFKB1THPOHIF1A | |
| SCHEMBL30038968 | 0.70 | PLAU (1.00) | PLAUMAPTNFKB1THPOHIF1A | |
| Hydrochloric Acid SCHEMBL4109114 | 0.68 | PLAU (0.95) | PLAUMAPTNFKB1THPOHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0014792-B1 | TETRAHYDRO-2H-BENZO(C)PYRROLES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE COMPOUNDS FOR USE AS THERAPEUTICALS | ELI LILLY AND COMPANY (US) | 1982-12-01 | — | — | EP | claimed |
| US-4235776-A | USED FOR TREATMENT OF PARKINSON'S DISEASE, PROLACTIN INHIBITORS, AND DOPAMINE AGONISTS | ELI LILLY AND COMPANY (US) | 1980-11-25 | — | — | US | claimed |
| WO-2014145512-A2 | POTENT SMALL MOLECULE INHIBITORS OF AUTOPHAGY, AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-09-18 | — | — | WO | disclosed |
| US-7524871-B2 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA, FACULTY OF PHARMACY (SI) | 2009-04-28 | — | — | US | disclosed |
| US-7112590-B2 | Thrombin inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2006-09-26 | — | — | US | disclosed |
| US-20050165034-A1 | Novel heterocyclic derivatives of tripeptides and tripeptide mimetics; (+-)-2-[3-[(benzylsulfonyl)amino]-6-methyl-2-oxo-1 (2H)-pyridinyl]-N-[(4,5,6,7-tetrahydro-2H-indazole-5-yl]acetamide; anticoagulants | UNIVERSITY OF LJUBLJANA, FACULTY OF PHARMACY (SI) | 2005-07-28 | — | — | US | disclosed |
| EP-1287018-B1 | THROMBIN INHIBITORS | LEK TOVARNA FARMACEVTSKIH (SI) | 2005-01-19 | — | — | EP | disclosed |
| EP-1451175-A1 | THROMBIN INHIBITORS | University of Ljubljana (SI) | 2004-09-01 | — | — | EP | disclosed |
| US-20030191139-A1 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA (SI) | 2003-10-09 | — | — | US | disclosed |
| WO-2003048155-A1 | THROMBIN INHIBITORS | UNIVERSITY OF LJUBLJANA (SI) | 2003-06-12 | — | — | WO | disclosed |
| EP-0014792-B1 | TETRAHYDRO-2H-BENZO(C)PYRROLES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE COMPOUNDS FOR USE AS THERAPEUTICALS | ELI LILLY AND COMPANY (US) | 1982-12-01 | — | — | EP | disclosed |
| US-4264622-A | TREATMENT OF PARKINSON*S DISEASE | ELI LILLY AND COMPANY (US) | 1981-04-28 | — | — | US | disclosed |
| US-4235776-A | USED FOR TREATMENT OF PARKINSON'S DISEASE, PROLACTIN INHIBITORS, AND DOPAMINE AGONISTS | ELI LILLY AND COMPANY (US) | 1980-11-25 | — | — | US | disclosed |
| EP-0014792-A1 | Tetrahydro-2H-benzo(c)pyrroles, their preparation, pharmaceutical compositions containing them and the compounds for use as therapeuticals | ELI LILLY AND COMPANY (US) | 1980-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191139-A1 | Thrombin inhibitors | TFPI, F2, SERPINC1 | PLAU 64/4885MAPT 3554/4885NFKB1 1410/4885 |
| US-20050165034-A1 | Novel heterocyclic derivatives of tripeptides and tripeptide mimetics; (+-)-2-[3-[(benzylsulfonyl)amino]-6-methyl-2-oxo-1 (2H)-pyridinyl]-N-[(4,5,6,7-tetrahydro-2H-indazole-5-yl]acetamide; anticoagulants | SERPINC1, TFPI, SERPINE1 | PLAU 69/4885MAPT 4838/4885NFKB1 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.